Verve Therapeutics (VERV) stock surged as promising trial data for cholesterol therapy VERVE-102 prompted Cantor Fitzgerald ...

Tuesday, Cantor Fitzgerald analyst Rick Bienkowski upgraded ... and clinically significant changes in safety measures such as ALT, AST, bilirubin, or platelets. This safety profile, combined ...

Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Outperform rating on AST SpaceMobile with a target price of $47. * In a cautious move, an analyst from Cantor Fitzgerald ...

Scotiabank reissued an “outperform” rating on shares of AST SpaceMobile in a report on Wednesday, March 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price ...

Scotiabank restated an “outperform” rating on shares of AST SpaceMobile in a research note on Wednesday, March 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued ...

AST SpaceMobile Inc is a satellite designer ... Click here for access. * An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $30.

While acknowledging that the stock is prone to volatility, Cantor Fitzgerald, and others, see AST SpaceMobile as a great way for investors to gain exposure to the burgeoning private satellite ...

Tuesday, Cantor Fitzgerald analyst Rick Bienkowski upgraded Verve Therapeutics ... and clinically significant changes in safety measures such as ALT, AST, bilirubin, or platelets. This safety profile, ...